MODERN CHI MED (01643) announced its interim results, showing a loss attributable to owners of the company of 25.9 million yuan, compared to a profit in the same period last year.

MODERN CHI MED (01643) announced its interim results for 2026, with revenue of approximately 118.5 million yuan, an increase of about 82.9% year-on-year. Gross profit was 22.1 million yuan, representing a year-on-year increase of approximately 36.4%. The loss attributable to owners of the company was 25.9 million yuan, a shift from profit to loss compared to the same period last year; the loss per share was 3.6 cents. The announcement stated that the increase in revenue was mainly due to a rise in orders from distributors in Hong Kong and mainland China. The loss was primarily attributed to increased promotional and marketing expenses and research and development costs, which were incurred to support the group's expansion in China and to enhance product quality and clinical value. Both expenditures are aimed at promoting the long-term development of the group.